17/05/2024  12:23:53 Var. -162.50 Volume Denaro- Lettera- Capitalizzazione di mercato Dividend Y. Rapporto P/E
9,280.00HUF -1.72% 3,135
Fatturato: 29.13 mill.
-Quantità in denaro: - -Quantità in lettera: - 1727.69 bill.HUF - 10.78

Descrizione business

Gedeon Richter Plc., headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Gabor Orban
Consiglio di amministrazione
István Hamecz, Katalin Erdei, Dr István Greiner, Tibor Horváth, Attila Szénási, Tamás Szolyák
Consiglio di sorveglianza
Prof Dr Szilveszter E. Vizi, Dr Ilona Hardy dr Pintérné, Erik Bogsch, Gábor Orbán, Dr Nándor Pál Ács, Gabriella Balogh, István Hamecz, Dr Péter Cserháti, Mrs Lászlóné Németh, Dr Anett Pandurics, Bálint Szécsényi, Balázs Szepesi, Dr Attila Chikán, Dr Róbert Jonathán Bedros, Dr Krisztina Gál, Dr Zoltán Matos, Dr Lívia Pavlik, Ferenc Sallai
 

Dati aziendali

Name: Chemical Works of Gedeon Richter PLC
Indirizzo: Gyömroi út 19-21.,HU-1103 Budapest
Telefono: +(36) 1-431-4000
Fax: +(36) 1-260-6650
E-mail: investor.relations@richter.hu
Internet: https://www.gedeonrichter.com/en/
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: -
Fine dell'anno finanziario: 31/12
Flottante libero: 74.93%
Data dell'IPO: 09/11/1994

Rapporti con gli investitori

Name: Katalin Ördög
IR telefono: +36-1-431 5764
IR Fax: -
IR e-mail: investor.relations@richter.hu

Company calendar

CW 32 | 06/08/2024 Interim Report 2nd Quarter/6 Months
CW 46 | 12/11/2024 Interim Report 3rd Quarter/9 Months